Shai Mulinari

Lund University — Sweden

Pharmacology, Toxicology and Pharmaceutics · Life Sciences

24h-index1.8kcitations119works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmaceutical industry and healthcare(54), Pharmaceutical Economics and Policy(45), Health Systems, Economic Evaluations, Quality of Life(22), Healthcare cost, quality, practices(17), Race, Genetics, and Society(8)

Publications119 total

Ambivalence about Race
Science studies·2025Open Access
Ambivalence about Race
transcript Verlag eBooks·2025Open Access
Offentligt eller privat? Svenska register behöver fånga upp vem som betalar för vårdbesöket
Lund University Publications (Lund University)·2025
Pharmaceutical company promotional payments to English general practices: a longitudinal study
BJGP Open·2025Open Access
Self-regulation of UK’s pharmaceutical industry
BMJ·2025
Results reporting for clinical trials led by medical universities and university hospitals in the nordic countries was often missing or delayed
Journal of Clinical Epidemiology·2025· 7 citedOpen Access
Unknowns of drug company payment disclosure: why the UK needs payment transparency legislation
BMJ evidence-based medicine·2025· 2 citedOpen Access
Pharmaceutical Industry Payments to Patient Organizations in Poland: Analysis of the Patterns, Evolution, and Structure of Connections
International Journal of Social Determinants of Health and Health Services·2024Open Access
Aligning digital biomarker definitions in psychiatry with the National Institute of Mental Health Research Domain Criteria framework
NPP—Digital Psychiatry and Neuroscience·2024· 3 citedOpen Access
Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015 and 2019: A content analysis
Health Policy·2024· 1 citedOpen Access
Broken beyond repair: self regulation of industry payments to clinicians and hospitals
BMJ·2024· 5 citedOpen Access
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals
Clinical and Translational Science·2024· 7 citedOpen Access
Patterns of company misconduct, recidivism, and complaint resolution delays: A temporal analysis of <scp>UK</scp> pharmaceutical industry self‐regulation within the European context
Regulation & Governance·2024· 6 citedOpen Access
Evaluating time to withdrawal of anti-cancer drug indications that received FDA’s accelerated approval
QJM·2024· 3 cited
Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015-2019: A content analysis
2024Open Access
Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019: An observational study
Health Policy and Technology·2024· 9 citedOpen Access
Delays in dealing with complaints against drug companies are growing, <i>BMJ</i> finds
BMJ·2024· 3 citedOpen Access
Results reporting for clinical trials led by medical universities and university hospitals in the Nordic countries was often missing or delayed
2024· 2 citedOpen Access
Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database
PLoS ONE·2023· 4 citedOpen Access
Authors’ reply to Fell
BMJ·2023
page 1 of 6Next →

Frequent Co-authors

Piotr Ozierański(18), Juan Merlo(12), Maria Wemrell(7), Emily Rickard(7), Andreas Vilhelmsson(6), Courtney Davis(4), Anna Bredström(4), Udo Häcker(3), Marcell Csanádi(3), Luc Martinon(3), Pierre-Alain Jachiet(3), Raquel Pérez-Vicente(2), S. V. Subramanian(2), Anne‐Christine Hornborg(2), Anna V. Zetterqvist(2), Akihiko Ozaki(2), Sten Axelsson Fisk(1), George Leckie(1), Bo Hedblad(1), Alice Fabbri(1)